Skip to content
Doseworth
Menu

FDA warning letter · #716699

TRYM Health: What the FDA Letter Means for What You Pay

Legal name: TRYM Health, Inc.

Activesemaglutidetirzepatide
Status

Operating

Concerns

marketing / labeling

Issued

September 2025

Response logged

Not logged

By Marla Whitfield, Pricing Editor

Primary source

Read the original letter on fda.gov →

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/trym-health-inc-dba-trym-health-716699-09092025

What FDA cited

Quoted verbatim from the letter dated

Read the full letter →

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://trymhealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.

  1. 1

    "Clinically Proven to Work"

  2. 2

    "Contains the same active ingredient as Mounjaro and ZepBound [sic]."

  3. 3

    "Contains the same active ingredient as Ozempic and Wegovy."

  4. 4

    Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.

Process

How a warning letter proceeds

  1. 1

    Letter issued

    September 2025

  2. 2

    15-working-day response window

    FDA gives the company 15 working days to respond in writing.

  3. 3

    Close-out, if issued

    FDA may post one once it is satisfied the cited issues have been corrected.

Is TRYM Health still operating?

trymhealth.com returned a live storefront when we checked in August 2026, still selling weight-loss, fitness and healthy-aging plans, and carrying a dated site notice from June 2026 about its email and support systems — evidence of an actively maintained operation rather than a parked domain.

What this means for what you pay

"Clinically Proven to Work" is four words with no product, no trial and no number attached to it, and that is precisely what FDA objected to: a claim that broad, sitting above a compounded product, borrows the evidence base of the approved drugs named further down the page. For a reader comparing subscription prices, the letter changes nothing about what TRYM charges or whether the plan is what it says it is. What it gives you is a way to grade the copy around the price — an unattached "clinically proven" is a claim about nothing in particular, and the specific comparison underneath it is the claim FDA said goes too far.

Has TRYM Health responded?

As of , FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence TRYM Health failed to respond.

Sources

Other letters in this index

View the full index →

Editorial disclaimer: An FDA warning letter is a public regulatory communication stating the agency's view. It is not a recall, a fine, a criminal charge, an injunction, or a finding that a company has broken the law.